NIKKEI 225
37,935.50 +307.02 (+0.82%) HANG SENG
17,624.11 +339.57 (+1.96%) CRUDE OIL
83.80 +0.23 (+0.28%) GOLD FUTURES
2,346.80 +4.30 (+0.18%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,412.59 +150.60 (+0.29%)
Akoya Biosciences, Inc. (AKYA)
After hours:
| Previous close | 3.8100 |
| Open | 3.9400 |
| Bid | 3.8000 x 200 |
| Ask | 3.8400 x 200 |
| Day's range | 3.7500 - 3.8500 |
| 52-week range | 3.0400 - 8.8000 |
| Volume | |
| Avg. volume | 182,820 |
| Market cap | 188.632M |
| Beta (5Y monthly) | 1.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance
- GlobeNewswire
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode™ Signature Panels and preliminary da
- GlobeNewswire
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023. “Akoya's successful 2023 performance reflects the high demand for our leading spatial biology solutions a
